More invasive prophylactic strategies worth it for BRCA1/2 mutation-positive women.

Předmět:	HEALTH insurance reimbursement HEALTH insurance rates BREAST cancer COST effectiveness MEDICAL economics
Zdroj:	PharmacoEconomics & Outcomes News; 11/27/2021, Vol. 892 Issue 1, p16-16, 1p
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Full text from SpringerLink